The Influence of Polymeric Versus Oligomeric Enteral Feeding on Tolerance and Nutritional Status in Paediatric Intensive Care: Prospective Randomized Pilot Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- The amount of energy delivery at 3rd day
研究概览
简要总结
Malnutrition is associated with negative impact on morbidity and mortality of critically ill patients. Therefore, in patients unable of peroral intake, the nutritional support is indicated. The preferred form of nutritional support is enteral, the more natural form, compared to parenteral. The enteral nutrition is cheaper and is associated with better outcomes and lower incidence of associated complications. The intolerance of enteral feeding is common in critically ill patients, and is associated with insufficient energy and protein intake, that could be linked with the complications such aspiration pneumonia. The optimization of enteral feeding tolerance is therefore one of the research priorities. Implementation of feeding protocols is associated with better tolerance. The enteral feeding could be administered as a oligomeric or polymeric formula. The are preliminary data from adult population pointing at better tolerance of oligomeric feeding formula.
详细描述
After Ethics Committee approval, all paediatric patients admitted to the paediatric intensive care unit (PICU) will underwent PICU screening. In case of eligible for inclusion in to the study, the baseline parameters a demographics will be evaluated together with the initial laboratory sampling after approval and singed the informed consent by the legal guardian of the patient. Patients will be randomized by the online randomizer to the oligomeric and polymeric enteral nutrition group.
Polymeric (control group): Patients indicated for at least 2 days of enteral nutrition by the gastric tube. The nutritional support will be initiated after initial haemodynamic stabilization (blood levels of lactate normalization, norepinephrine infusion <0,1 ug/kg/min) in the 48-hours interval from admission in form of bolus administration of polymeric formula. The initial dose will be 10% of the target volume (by Schofield equation). The gastric residual volume will be evaluated after 4 hours from bolus dose. In case of gastric residual volume lower than half of previously administered dose, the next dose will be elevated by 10% with the aim to reach the target dose in 48 hours. In case of higher residual volume, the same amount will be administered with the metoclopramid (3 times per day). In case of persistent residual volume higher than half of initial dose in 12 hours, the erythromycin will be initiated for 3 days. The bolus enteral feeding will be administered at the predefined time 5/day (6:00, 10:00, 14:00, 18:00, 22:00). The last gastric decompression is planned ad 24:00. The aim is to reach energetic goal defined by Schofield equation.
Interventional (oligomeric group): Patients indicated for at least 2 days of enteral nutrition by the gastric tube. The nutritional support will be initiated after initial haemodynamic stabilization (blood levels of lactate normalization, norepinephrine infusion <0,1 ug/kg/min) in the 48-hours interval from admission in form of bolus administration of oligomeric formula. The initial dose will be 10% of the target volume (by Schofield equation). The gastric residual volume will be evaluated after 4 hours from bolus dose. In case of gastric residual volume lower than half of previously administered dose, the next dose will be elevated by 10% with the aim to reach the target dose in 48 hours. In case of higher residual volume, the same amount will be administered with the metoclopramid (3 times per day). In case of persistent residual volume higher than half of initial dose in 12 hours, the erythromycin will be initiated for 3 days. The bolus enteral feeding will be administered at the predefined time 5/day (6:00, 10:00, 14:00, 18:00, 22:00). The las gastric decompression is planned ad 24:00. The aim is to reach energetic goal defined by Schofield equation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
The patients and the legal guardians will be blinded
入排标准
- 年龄范围
- 1 Month 至 19 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PICU patients indicated for nutritional support by enteral feeding (gastric or jejunal)
排除标准
- •Enteral feeding contraindicated
- •Persistent haemodynamic instability
- •Informed consent not signed
- •Acute pancreatitis
- •Recent upper gastrointestinal surgery
- •Gut perforation
结局指标
主要结局
The amount of energy delivery at 3rd day
时间窗: on the 3rd day after study inclusion
The amount of delivered energy at 3rd day according to the defined energy goal by derived from Schofield equation (defined after 15 enteral bolus doses)
The amount of protein delivery at 3rd day
时间窗: on the 3rd day after study inclusion
The amount of delivered protein at 3rd day according to the defined protein goal by derived from Schofield equation (defined after 15 enteral bolus doses)
次要结局
- The time needed to achieve the protein target(in 7 days after study initiation)
- The mean gastric residual volume(in 7 days after study initiation)
- The time needed to achieve the energy target(in 7 days after study initiation)
- The daily protein delivery(in 7 days after study initiation)
- The daily gastric residual volume(in 7 days after study initiation)
- The daily number of stool(in 7 days after study initiation)
- Nutritional parameters 1 - prealbumin(in 7 days after study initiation)
- The amount of energy delivery at 5th day(on the 5th day after study inclusion)
- The amount of protein delivery at 5th day(on the 5th day after study inclusion)
- The amount of energy delivery at 7th day(on the 7th day after study inclusion)
- The amount of protein delivery at 7th day(on the 7th day after study initiation)
- The daily energy delivery(in 7 days after study initiation)
- The time to first stool(in 7 days after study initiation)
- Nutritional parameters 1 - albumin(in 7 days after study initiation)
研究者
Petr Štourač, MD
Clinical Professor
Brno University Hospital